Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to
evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously
treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF
therapy, and, if RAS wild type, an anti-EGFR therapy.